SLC5A2 and type 2 diabetes mellitus: In this study, we have demonstrated, for the first time, that the SGLT2 inhibitor empagliflozin, the DPP4 inhibitor linagliptin, and a combination of these agents, could reactivate glomerular autophagy in db/db mice, a model of type 2 diabetes.